(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 113.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
X4 Pharmaceuticals's revenue in 2026 is $9,014,000.On average, 6 Wall Street analysts forecast XFOR's revenue for 2026 to be $913,957,854, with the lowest XFOR revenue forecast at $665,519,775, and the highest XFOR revenue forecast at $1,069,585,353. On average, 6 Wall Street analysts forecast XFOR's revenue for 2027 to be $921,220,471, with the lowest XFOR revenue forecast at $600,816,464, and the highest XFOR revenue forecast at $1,089,392,489.
In 2028, XFOR is forecast to generate $9,681,916,794 in revenue, with the lowest revenue forecast at $3,817,495,376 and the highest revenue forecast at $18,182,950,995.